Background:Though many countries,including China,are moving towards malaria elimination,malaria remains a major global health threat.Due to the spread of antimalarial drug resistance and the need for innovative medica...Background:Though many countries,including China,are moving towards malaria elimination,malaria remains a major global health threat.Due to the spread of antimalarial drug resistance and the need for innovative medical products during the elimination phase,further research and development(R&D)of innovative tools in both epidemic and elimination areas is needed.This study aims to identify the trends and gaps in malaria R&D in China,and aims to offer suggestions on how China can be more effectively involved in global malaria R&D.Methods:Quantitative analysis was carried out by collecting data on Chinese malaria-related research programmes between 1985 and 2014,invention patents in China from 1985 to 2014,and articles published by Chinese researchers in PubMed and Chinese databases from 2005 to 2014.All data were screened and extracted for numerical analysis and were categorized into basic sciences,drug/drug resistance,immunology/vaccines,or diagnostics/detection for chronological and subgroup comparisons.Results:The number of malaria R&D activities have shown a trend of increase during the past 30 years,however these activities have fluctuated within the past few years.During the past 10 years,R&D on drug/drug resistance accounted for the highest percentages of research programmes(32.4%),articles(55.0%in PubMed and 50.6%in Chinese databases)and patents(45.5%).However,these R&D activities were mainly related to artemisinin.R&D on immunology/vaccines has been a continuous interest for China’s public entities,but the focus remains on basic science.R&D in the area of high-efficiency diagnostics has been rarely seen or reported in China.Conclusions:China has long been devoted to malaria R&D in multiple areas,including drugs,drug resistance,immunology and vaccines.R&D on diagnostics has received significantly less attention,however,it should also be an area where China can make a contribution.More focus on malaria R&D is needed,especially in the area of diagnostics,if China would like to contribute in a more significant way to global malaria control and elimination.展开更多
基金This research was supported by China UK Global Health Support Programme funded by UK DFID(grant no.GHSP-CS-OP301)China Postdoctoral Science Foundation(grant no.2014 M560027)National Natural Science Foundation of China(grant no.71503015)。
文摘Background:Though many countries,including China,are moving towards malaria elimination,malaria remains a major global health threat.Due to the spread of antimalarial drug resistance and the need for innovative medical products during the elimination phase,further research and development(R&D)of innovative tools in both epidemic and elimination areas is needed.This study aims to identify the trends and gaps in malaria R&D in China,and aims to offer suggestions on how China can be more effectively involved in global malaria R&D.Methods:Quantitative analysis was carried out by collecting data on Chinese malaria-related research programmes between 1985 and 2014,invention patents in China from 1985 to 2014,and articles published by Chinese researchers in PubMed and Chinese databases from 2005 to 2014.All data were screened and extracted for numerical analysis and were categorized into basic sciences,drug/drug resistance,immunology/vaccines,or diagnostics/detection for chronological and subgroup comparisons.Results:The number of malaria R&D activities have shown a trend of increase during the past 30 years,however these activities have fluctuated within the past few years.During the past 10 years,R&D on drug/drug resistance accounted for the highest percentages of research programmes(32.4%),articles(55.0%in PubMed and 50.6%in Chinese databases)and patents(45.5%).However,these R&D activities were mainly related to artemisinin.R&D on immunology/vaccines has been a continuous interest for China’s public entities,but the focus remains on basic science.R&D in the area of high-efficiency diagnostics has been rarely seen or reported in China.Conclusions:China has long been devoted to malaria R&D in multiple areas,including drugs,drug resistance,immunology and vaccines.R&D on diagnostics has received significantly less attention,however,it should also be an area where China can make a contribution.More focus on malaria R&D is needed,especially in the area of diagnostics,if China would like to contribute in a more significant way to global malaria control and elimination.
